Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies (Q38092582)

28 August 2017

Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies (English)

1 reference

28 August 2017

L G M Daenen

1

1 reference

28 August 2017

J M Houthuijzen

2

1 reference

28 August 2017

G A Cirkel

3

1 reference

28 August 2017

J M L Roodhart

4

1 reference

28 August 2017

Y Shaked

5

1 reference

28 August 2017

E E Voest

6

1 reference

28 August 2017

language of work or name

English

0 references

publication date

25 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

33

1 reference

28 August 2017

11

1 reference

28 August 2017

1341-1347

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2013.94

28 August 2017

0 references

cites work

Tumors as organs: complex tissues that interface with the entire organism

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Putting tumours in context

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Accessories to the crime: functions of cells recruited to the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Environment-mediated drug resistance: a major contributor to minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

A perspective on cancer cell metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Drug resistance and the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Stromal biology and therapy in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Acquired multicellular-mediated resistance to alkylating agents in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Chemotherapy sensitivity and resistance assays: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Clinical experience with Hedgehog pathway inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

The anti-angiogenic basis of metronomic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Peering into the aftermath: The inhospitable host?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Microenvironmental regulation of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Mechanisms of resistance to vascular endothelial growth factor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

The angiogenic profile of colorectal cancer patients following open or laparoscopic colectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Increased number of mesenchymal stem cell-like cells in peripheral blood of patients with bone sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

DNA damage-mediated induction of a chemoresistant niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Senescence-messaging secretome: SMS-ing cellular stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Repopulation of cancer cells during therapy: an important cause of treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Repopulation of tumour cells between cycles of chemotherapy: a neglected factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Exploiting tumour hypoxia in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

ONCOGENESIS: Landscaping the Cancer Terrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Role of bone marrow-derived cells in tumor angiogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Cell-cycle arrest versus cell death in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Integrin inhibitors reaching the clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.94

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.94

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference